Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.

This study evaluated the safety and efficacy of batroxobin in treating hyperfibrinogenemia for secondary stroke prevention. Patients with ischemic stroke or transient ischemic attack (TIA) were measured for plasma fibrinogen levels. Selected participants had concomitant hyperfibrinogenemia (plasma fibrinogen > or = 3.0 g/l). Patients enrolled between 1 July 2003 and 31 December 2004 were treated with batroxobin; patients enrolled between 1 January 2002 and 30 June 2003 were treated without batroxobin. Batroxobin was administered intermittently via intravenous injection at 3-monthly intervals. Patients in both groups were followed for 1 year. Any cerebrovascular events and suspected adverse events were recorded. In total, 112 ischemic stroke/TIA patients with concomitant hyperfibrinogenemia were enrolled, 52 being treated with batroxobin and 60 without batroxobin. Six patients (11.5%) with batroxobin and 16 patients (26.7%) without batroxobin had recurrent cerebral ischemic events during follow-up. Stroke/TIA recurrence in patients without batroxobin was higher than that in patients with batroxobin (P < 0.05). Two patients with batroxobin and two patients without batroxobin developed hemorrhagic stroke during follow-up. There were five deaths (9.6%) in the batroxobin group, and seven deaths (11.7%) in the nonbatroxobin group during follow-up (P > 0.05). Intermittent intravenous injection of batroxobin can efficiently reduce the risk for stroke/TIA recurrence in patients with concomitant hyperfibrinogenemia.     

岛状皮瓣修复瘢痕性睑外翻

目的探讨眼轮匝肌蒂颞部岛状皮瓣与颞浅动脉蒂反流轴型耳后岛状皮瓣在修复瘢痕性睑外翻中的应用,提高睑外翻矫正后所致皮肤缺损的美学修复效果。方法自1998年2月以来,对18例瘢痕性睑外翻,采用眼轮匝肌蒂颞部岛状皮瓣旋转180°移位修复13例,皮瓣最大面积2.7cm×3.6cm;采用颞浅动脉蒂反流轴型耳后岛状皮瓣经面部皮下隧道转移修复5例,皮瓣最大面积3.1cm×5.4cm。结果1例反流轴型耳后岛状皮瓣术后出现静脉回流障碍,经对症处理后仅皮瓣远端部分表皮坏死,Ⅱ期植皮后治愈,其余17例皮瓣完全成活。随访6个月,睑外翻矫正,皮瓣颜色、质地与眼周皮肤相近,供区瘢痕不明显。结论根据睑外翻程度,可制备颞部岛状皮瓣或耳后岛状皮瓣转移。前者适用于修复较小面积的皮肤缺损,后者适用于修复较大面积的皮肤缺损。     

灵芝菌合剂中灵芝多糖含量的测定

目的：探讨灵芝菌合剂中灵芝多糖含量的检测方法。方法：采用分光光度法，以无水葡萄糖为对照品，检测波长为490nm。结果：此方法在0～120μg范围内线性关系良好，灵芝多糖的平均回收率为99．09%。RSB为1．14％。结论：本法简便快捷，准确度高，重现性好，可作为本制剂的质控方法。     

针刺对肾血管性高血压大鼠的降压效应

目的　探讨针刺对肾血管性高血压大鼠的降压作用及其神经 -内分泌调节机制。方法　采用二肾一夹法制备高血压大鼠模型 ,测定实验各组大鼠血浆内皮素 (ET)、一氧化氮 (NO)含量和心率变异性 (HRV)的动态变化。结果　与模型组相比 ,针刺组血压 (BL 2 3:19.1± 1.1k Pa,ST36:18.1± 2 .5 k Pa)及 ET水平明显下降 (P<0 .0 1) ,其中针刺肾俞组血浆 ET水平 (91.3± 9.45 pg/ ml)较足三里组 (10 8.48± 13.0 6pg/ ml)下降更明显 (P<0 .0 5 ) ;针刺治疗组血浆 NO水平 (BL 2 3:5 0 .3±12 .7μmol/ ml,ST 36:49.71± 8.49μm ol/ m l)显著升高 (P<0 .0 5 )。足三里组针刺后 L F/ HF比值与模型组无明显差异 ,而肾俞组 L F/ HF值 (0 .5 7± 0 .13)明显低于模型组及足三里组 (0 .86± 0 .2 5 )。结论　针刺能降低肾血管性高血压模型大鼠动脉血压 ,肾俞与足三里两穴无明显差异 ,其作用机制可能与自主神经系统、NO及 ET参与的神经内分泌调节作用相关。     

应用VTK技术建立唇腭裂可视化模型

目的:寻求一种高效率、高精度建立唇腭裂患者颌面部可视化模型的方法.方法:利用薄层CT获取原始数据,运用k-均值聚类算法进行图像分割,结合VTK(Visualization Toolkit)技术进行可视化模型的建立.结果:建立了更为精确的唇腭裂患者颌面部的可视化模型,总结出了一种更为方便高效的通用可视化建模方法.结论:应用VTK方法建立可视化模型,软件开发周期更短,精度更高,应用更广泛.     

Incidence of Chest Tube Malposition in the Critically Ill: A Prospective Computed Tomography Study

Background: Malposition of percutaneously inserted chest tubes is considered as a rare complication in critically ill patients. Its incidence, however, remains uncertain. The aims of the study were to assess the true incidence of chest tube malposition in critically ill patients and to identify predicting factors.

Methods: The authors prospectively studied 122 chest tubes percutaneously inserted in 75 consecutive critically ill patients. For clinical reasons independent of the study, thoracic computed tomography scanning was performed in 63 patients, allowing direct visualization of 106 chest tubes. Based on these findings, chest tube position was classified as intrapleural, intrafissural, or intraparenchymal. Factors predicting chest tube malposition were analyzed by univariate and multivariate analysis.

Results: The mean delay between chest tube placement and thoracic scan was 3.5 +/- 2.9 days. Twenty-two chest tubes were diagnosed as being intrafissural (21%), and 10 were diagnosed as being intraparenchymal (9%). The only predicting factor associated with the risk of malposition was the use of a trocar for the percutaneous insertion of the chest tube (P = 0.032).     

泰素蒂加顺铂治疗进展期NSCLC的临床研究

目的观察泰素蒂加顺铂方案治疗进展期非小细胞肺癌的临床疗效、毒副作用。方法收集可评价疗效的进展期非小细胞肺癌50例,以泰素蒂加顺铂方案进行化疗,泰素蒂75 mg/m2静脉滴注,第1天;顺铂25 mg/m2～30 mg/m2静脉滴注,第2天～第5天,每3周为一个周期,2～3周期后评价疗效和毒副反应并随访。结果50例患者中,总有效率为50.0 %,其中初治病例为53.1 %,复治病例为44.4 %,初复治病例间差异无显著性(P >0.05)。中位缓解期为5个月。中位生存期为9.5个月,1年生存率为61.0 %。毒副反应主要为骨髓抑制,白细胞下降达Ⅲ度、Ⅳ度者52.0 %,血小板下降达Ⅲ度、Ⅳ度者为14.0 %。血红蛋白下降不严重。其他毒副反应还有脱发、过敏反应、水钠潴留、静脉炎、末梢神经炎、口腔炎、腹泻等,但发生率均较低。结论泰素蒂加顺铂方案治疗进展期非小细胞肺癌,特别是复发病例,临床疗效比较满意,毒副反应能够耐受。辅以G蛳CSF可防治重度的骨髓抑制,有较好的临床应用价值。     

大鼠脑缺血时脑细胞膜磷脂含量变化

采用SD大鼠一侧大脑中动脉阻断致局限性脑缺血模型。脑缺血后迅速断头置于液氮中,HPLC外标定量法测定各磷脂组分。观察脑缺血1、5、15、60、360min时脑细胞膜磷脂含量变化。结果显示,PI在缺血早期显著低于对照组(P<0.01～0.05);PE、PC早期仅呈下降趋势,PE在缺血60min组、PC缺血360min组显著低于对照组(P<0.01～0.05)。PS在缺血全过程中变化轻微(P>0.05)。提示磷脂降解与脑缺血存在一定关系,缺血早期首先出现脑细胞膜功能磷脂降解,膜结构磷脂则在缺血后期出现显著变化,且PE较PC优先降解。     

3种氟喹诺酮类药物抗生素后效应的研究

应用AVANTAGF分析仪的光密度法测定了环丙沙星（CPLX）、氧氟沙星（OFLX）和氟罗沙星（FLRX）的抗生素后效应（PAE）．结果表明氟喹诺酮类抗菌药物对革兰氏阳性球菌和革兰氏阴性杆菌均产生明显的PAE．并随抗菌药物浓度的增大、对受试菌的PAE逐渐延长．呈现了明显的浓度依赖性；3种抗菌药物对铜绿假单胞菌的PAE都较长．MIC均较小．显示了良好的杀菌效果：氯罗沙星对除金葡球菌之外的受试菌的PAE均比其它2药较长．PAE的存在提示在临床设计给药方案时．可适当延长给药间期．减少给药次数与剂量．仍能维持抗菌效果。     

肺癌脑转移83例临床分析

我所内科１９８８￣１９９３年收治肺癌患者１００６例，脑转移８３例，占８．２５％，由于治疗方法不同，其预后极其不同。手术切除加放疗化疗与单纯放疗化疗的生存率有显著性差异（Ｐ〈０．０５），放疗化疗综合组疗效预后好于单一治疗组（Ｐ〈０．０５）。因此在肺癌确诊后应常规作脑影像学检查，可早期诊断，这是提高疗效和生存捏的重要因素。